Author:
Falkenbach Fabian,Steuber Thomas,Graefen Markus
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. Amin MB, Edge SB, Greene FL et al (2017) AJCC cancer staging manual. Springer
2. Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974–2986
3. Bauckneht M, Checcucci E, Cisero E et al (2023) The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur J Nucl Med Mol Imaging
4. Blanchard P, Vickers AJ (2022) Prostatectomy in patients with oligometastatic hormone-sensitive prostate cancer? Not yet. Eur Urol 5:526–527
5. Boevé LMS, Hulshof M, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75:410–418